Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Evommune (EVMN) Revenue (2024 - 2025)

Evommune (EVMN) has disclosed Revenue for 2 consecutive years, with $10.0 million as the latest value for Q3 2025.

  • Quarterly Revenue rose 58923.53% to $10.0 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $10.0 million through Dec 2025, changed N/A year-over-year, with the annual reading at $13.0 million for FY2025, 85.71% up from the prior year.
  • Revenue for Q3 2025 was $10.0 million at Evommune, up from -$17000.0 in the prior quarter.
  • The five-year high for Revenue was $10.0 million in Q3 2025, with the low at -$17000.0 in Q3 2024.